Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 16.18%
- Healthy long term growth as Operating profit has grown by an annual rate 38.24%
- Company has very low debt and has enough cash to service the debt requirements
2
With ROE of 22.75%, it has a very attractive valuation with a 1.58 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 252,768 Million (Small Cap)
7.00
NA
0.01%
-0.25
23.09%
1.84
Revenue and Profits:
Net Sales:
40,145 Million
(Quarterly Results - Jun 2025)
Net Profit:
4,669 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.26%
0%
1.26%
6 Months
15.04%
0%
15.04%
1 Year
-10.16%
0%
-10.16%
2 Years
-15.83%
0%
-15.83%
3 Years
13.95%
0%
13.95%
4 Years
-45.31%
0%
-45.31%
5 Years
9.88%
0%
9.88%
JEOL Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.90%
EBIT Growth (5y)
38.24%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.37
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
1.36
Tax Ratio
25.13%
Dividend Payout Ratio
29.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.02%
ROE (avg)
16.18%
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
1.58
EV to EBIT
5.29
EV to EBITDA
4.61
EV to Capital Employed
1.73
EV to Sales
0.95
PEG Ratio
0.17
Dividend Yield
0.01%
ROCE (Latest)
32.67%
ROE (Latest)
22.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
40,145.00
36,354.00
10.43%
Operating Profit (PBDIT) excl Other Income
6,981.00
5,208.00
34.04%
Interest
22.00
27.00
-18.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4,669.00
3,896.00
19.84%
Operating Profit Margin (Excl OI)
144.30%
112.10%
3.22%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 10.43% vs 26.80% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 19.84% vs 125.99% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
196,695.00
174,336.00
12.83%
Operating Profit (PBDIT) excl Other Income
40,803.00
32,278.00
26.41%
Interest
120.00
88.00
36.36%
Exceptional Items
-12,315.00
-727.00
-1,593.95%
Consolidate Net Profit
18,688.00
21,704.00
-13.90%
Operating Profit Margin (Excl OI)
181.10%
157.90%
2.32%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 12.83% vs 7.16% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -13.90% vs 21.73% in Mar 2024
About JEOL Ltd. 
JEOL Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






